anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vital pulp therapy has been traditionally recommended only in teeth with reversible pulpitis with no periapical pathologies or in teeth with either mechanical pulp exposure or recent traumatic exposure. Clinical symptoms such as characteristics, severity and intensity of pre-operative pain do not accurately talk about the status of the pulp inflammation and the depth of involvement. It has been demonstrated that there is no precise correlation between clinical symptoms and the histopathological status of the pulp, mainly in case of irreversible pulpitis, that might lead to a wrong diagnosis. Vitality tests such as cold test or electric pulp tests reveal only whether the pulp is responsive to respective stimuli or not. According to new Wolters pulpal clinical classification, Moderate pulpitis exhibit symptoms of prolonged reaction to cold, which can last for minutes, possibly percussion sensitive and spontaneous dull pain which corresponds to irreversible pulpitis. Vital pulp therapy is suggested to be the choice of treatment for such cases. It has been suggested that infection is often a cause of inflammation, an inflamed pulp should be able to heal if the source of infection is eliminated as in other body organs. Removal of trigger (i.e. caries) followed by application of biocompatible material which makes a good seal in a sterile environment has potential to allow for recovery and healing of the inflamed pulp tissue which is thought to be beyond recovery. Partial caries removal, which involves complete removal of carious dentine from the surrounding cavity walls, followed by the partial removal of infected dentin at the pulpal wall which reduce chances of pulp exposure followed by placement of medicament for Indirect pulp capping. Whereas during Complete caries removal, caries is completely removed from surrounding walls as well as on pulpal wall which increase the chances of pulp exposure followed by placement of medicament for Direct pulp capping procedure. Based on this premise, IPC can be considered as minimally invasive approach for the management of teeth with inflamed pulps in place of the conventional approach of direct pulp capping, partial pulpotomy or full pulpotomy in adults.

Research Question Does Indirect Pulp Capping have comparable outcome with Direct pulp capping after partial caries removal in deeply carious mature permanent molars with clinical signs indicative of moderate pulpitis? P (Population) - Deeply carious mature Permanent Mandibular molars with clinical signs indicative of moderate pulpitis I (Intervention) - Partial caries removal followed by Indirect pulp capping C (Comparison) - Complete caries removal followed by Direct pulp capping O (Outcome) - Assessment of clinical and radiographic success at 12 months follow up.

* To assess incidence and reduction in pain post operatively at every 24 hours till 1 week.
Cholestyramine for Oral Suspension, USP powder, the chloride salt of a basic anion exchange resin, a cholesterol lowering agent, is intended for oral administration. Cholestyramine resin is quite hydrophilic, but insoluble in water. Cholestyramine resin is not absorbed from the digestive tract. Each Nine grams of Cholestyramine for Oral Suspension, USP powder contain 4 grams of cholestyramine resin. It is represented by the following structural formula:

Representation of structure of main polymeric groups

Inactive ingredients: citric acid anhydrous, fructose, mono ammonium glycyrrhizinate, pectin, propylene glycol alginate, sorbitol, sucrose, xanthan gum, natural and artificial orange flavor, D&C yellow No. 10 aluminum lake, FD&C yellow No. 6 aluminum lake.
[Problem] To provide, inter alia, an information processing system that can swiftly and easily present information desired by a user with regard to a biological substance and the like. [Solution] According to one aspect of the present invention, the information processing system is provided. This information processing system is configured so as to execute each of the following steps. In a reception step, a first input pertaining to a first substance selected from the group consisting of biological substances and drugs is received from a user. In a specification step, presentation information to be presented to the user is specified on the basis of the first input and pre-set reference information. The reference information is text information pertaining to the biological substance and/or drug and an experimental operation to be performed on these. The presentation information includes: an experimental operation that can be performed on the first substance; and/or a second substance selected from the group consisting of biological substances and drugs having relevance with the first substance. In a display control step, control is performed so as to display the specified presentation information.
One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
Sick sinus syndrome (SSS), also known as sinoatrial node dysfunction, has been widely concerned by the medical community. The incidence rate of SSS is increasingly, which poses a great threat to public health. Through decades of repeated research in the medical field, great progress has been made in the pathogenesis of SSS and the interaction mechanism between SSS and other cardiovascular diseases. In this paper, we pay special attention to the mental stimulation factors under various pressures such as society and work, and the influence of smoking, drinking, and unhealthy diet on the pathogenesis of SSS. It also explains the mechanism of negative factors in the pathogenesis of SSS. These unhealthy lifestyle will lead to the occurrence of sinoatrial node disease and arrhythmia, and then induce SSS. Therefore, in the premise of increasing incidence rate of SSS and difficult to cure, how to avoid these harmful factors and ensure a healthy lifestyle is extremely important for preventing and treating SSS. This study also has guiding significance for the daily life of high-risk population of SSS and reducing the mortality of SSS patients.
Participants in the control group will receive a smoking cessation booklet published by the Hong Kong Council on Smoking and Health that provided information on the negative health consequences of smoking, reasons to quit, strategies for quitting, smoking cessation services available in Hong Kong, and a public Quitline number (usual care). Participants will also receive a monthly health education for three months that provides general health information and sharing sessions, which is one of the routine care for smokers during the first 3-4 months after they seek help for smoking problem (waiting period for further intervention).
PURPOSE: To provide a composite film composed of an occlusion layer and a holding layer having a specific constitution and composed of a silicone polymer containing a gelatinized active aqueous phase as an internal phase component and effective for impregnating a drug, etc., in the form of an aqueous solution into the skin by a skin permeation effect. CONSTITUTION: This composite film is composed of an occlusion layer and a holding layer holding an active aqueous phase in sealed state and bonded to a removable protection member. The silicone polymer constituting the holding layer is partially cross-linked to exhibit autohesive property to the surface to be treated. The holding layer contains 10-50wt.% of a gelatinized active aqueous phase and the average thickness of the layer is 0.5-3mm and thinner than the thickness (0.2-4mm) of the protection layer. The holding layer of the side opposite to the occlusion layer contains a web (e.g. a perforated plastic sheet or a perforated nonwoven fabric sheet) having a dimension of 10-1,000 mesh/cm<2> and a thickness of 0.01-1.5mm and thinner than the thickness of the occlusion layer.
The invention relates to the field of skin care products, and particularly discloses a whitening composition, a preparation method and application, wherein the whitening composition comprises the following components in percentage by mass: 0.5-5.0% of ribes nigrum fruit extract and 0.5-3.0% of inositol. The whitening composition is obtained by reasonably matching the ribes nigrum fruit extract and inositol according to a specific proportion. The ribes nigrum fruit extract is rich in natural vitamin C, and can reduce the activity of the tyrosinase and reduce the formation of melanin. Natural vitamin C has limited transdermal absorption and the degree of absorption limits the efficacy of the product. Inositol can enhance the delivery of other ingredients in the cosmetic formulation, thereby enhancing the use effect of the cosmetic. Inositol can promote the transdermal absorption of the ribes nigrum fruit extract and enhance the repairing and anti-aging effects of the ribes nigrum fruit extract. The whitening composition can be applied to various product forms of whitening cosmetics, and has the characteristics of simple preparation method, wide application and capability of meeting market requirements.
Chronic obstructive pulmonary disease (COPD) is a common disease with substantial associated morbidity and mortality. COPD is the third leading cause of death in the US and claimed 133,965 US lives in 2009. In 2011 12.7 million US adults were estimated to have COPD. However, approximately 24 million US adults have evidence of impaired lung function, indicating an under diagnosis of COPD. COPD also has a potentially harmful economic impact. In 2010, COPD resulted in over 10 million office visits, nearly 1.5 million emergency department visits, 700,000 hospitalizations, and 133,575 deaths in the US. In 2010, US total medical treatment costs attributed solely to COPD (i.e., excluding comorbidities) were estimated to be $32.1 billion with an additional $3.9 billion in COPD costs resulting from worker absenteeism. Even in industrialized countries such as the US, where anti-smoking initiatives have been relatively successful, the legacy of past smoking behavior in aging populations ensures that the COPD burden will unavoidably continue to climb over the next 20 to 30 years. Adherence rates for inhaled combination therapy is poor (average 3.9 refills per year). COPD patients with lower adherence tend to have higher overall healthcare costs, as demonstrated in a 24 month study of 33,816 patients in the US, which found: Patients continuing therapy had lower costs of care by $3764 compared with patients who had ceased to take their maintenance therapy. COPD patients with higher adherence to prescribed regimens experienced fewer hospitalizations and lower Medicare costs (-$2185) than those who exhibited lower adherence behaviors. Given the poor adherence with inhaled combination therapy seen in patients with COPD, and associated morbidity/mortality and economic costs, the present study is being conducted to see if medication reminders can be used to improve adherence in this population.
Eligible participants will be administered peginterferon alpha-2a \[Pegasys\] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of \<15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
The pilot project will examine the effects of a brief, one-session computerized intervention delivered to Veterans seeking treatment for an opioid use disorder. The opioid epidemic in the United States (US) is having a disproportionate impact on Veterans. Indeed, Veterans are twice as likely to die from an accidental opioid overdose than members of the general population, even after accounting for gender and age distribution. Although many individuals with an opioid addiction seek treatment, a large proportion drop out prematurely and/or relapse, highlighting the need to identify modifiable factors that may contribute to this process. One variable that may be useful in understanding attrition in addiction treatment is anxiety sensitivity (AS). AS is a well-established psychological risk factor reflecting the tendency to fear anxious arousal due to the belief that this arousal will have harmful physical, mental, and/or social consequences. AS is elevated in opioid use populations and predicts treatment dropout among opioid users. Importantly, research suggests that AS is highly malleable. Despite this, to our knowledge no published research to date has systematically explored the utility of AS reduction protocols among opioid users. The first aim of the current project is to test the acceptability and feasibility of a brief, one-session Computerized AS Treatment (CAST) delivered to Veterans seeking treatment for an opioid use disorder. Because this is a pilot project and the study will likely be underpowered to detect treatment effects, we will not emphasize symptom reduction. Nevertheless, a second aim of the current project is to examine the utility of CAST by gathering data on symptom change. Finally, a third aim of the current project is to examine the effects of CAST on rates of attendance and retention in a substance use disorder treatment (SUDT) program.
A two-generation reproductive toxicity study was performed to evaluate the effects of cerium nitrate on the development of the parent, offspring, and third generation of Sprague-Dawley (SD) rats. A total of 240 SD rats (30 rats/sex/group) were randomly divided into four dosage groups according to body weight: 0 mg/kg, 30 mg/kg, 90 mg/kg, and 270 mg/kg. The rats were administered different dosages of cerium nitrate by oral gavage. There were no observed changes related to cerium nitrate in body weight, food consumption, sperm survival rate, motility, mating rate, conception rate, abortion rate, uterine plus fetal weight, uterine weight, corpus luteum number, implantation rate, live fetus number (rate), stillbirth number (rate), absorbed fetus number (rate), appearance, visceral, and skeletal in rats of each generation dosage group. In addition, the pathological findings showed no significant lesions associated with cerium nitrate toxicity in all tissues and organs, including reproductive organs. In conclusion, the present study showed that long-term oral gavage of cerium nitrate at 30 mg/kg, 90 mg/kg, and 270 mg/kg had no significant effect on reproduction and the developmental ability of their offspring in rats. The no-observed-adverse-effect level (NOAEL) of cerium nitrate in SD rats was higher than 270 mg/kg.
PROBLEM TO BE SOLVED: To obtain an IL-4 production inhibitor useful as a therapeutic agent for atopic dermatitis and allergic diseases by including a steam distillate of eucalypti as an active ingredient. SOLUTION: This inhibitor comprises a fraction obtained by steam-distilling leaves, twigs, flowers or fruits of eucalypti (evergreen abores belonging to the genus Myptus globulus of the family Myrtaceae or the affinitive plants therefor), as an active ingredient. The daily dosage of the inhibitor is pref. ordinarily 0.1 to 2,000 mg per adult when used as a cosmetic, drug or aquasi- drug. By including e.g. the inhibitor, a base material for external use and other medicinal properties, there is obtained an agent composition for external use for skin suitable for preventing or treating atopic dermatitis.
WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
PROBLEM TO BE SOLVED: To produce an iridescent composition, exhibiting a low viscosity even at a high concentration of an iridescent agent, excellent in dispersibility and assuming an excellent iridescence and to provide a method for producing the composition. SOLUTION: This iridescent composition comprises (A) a glycol ester of a fatty acid, (B) a monoalkylolamide of a fatty acid, (C) an amphoteric surfactant and (D) water. The amounts of the components based on 100 pts.wt. glycol ester of the fatty acid A are 10-25 pts.wt. monoalkylolamide ester of the fatty acid B and 5-30 pts.wt. amphoteric surfactant C. The composition has a crystal of the glycol ester of the fatty acid A, having 20-60wt.% content of the glycol ester of the fatty acid A, 2-20μm average particle diameter and <=0.3μm thickness.
INTRODUCTION: Low back disorder (LBD) is a major cause of disability worldwide. Inflammation results in proliferation of cytokines or consequent degradation products (collectively known as inflammatory biomarkers) that activate pain pathways which can result in non-specific LBD. This systematic review and meta-analysis aim to evaluate the relationship between inflammatory biomarkers and clinical outcomes in patients with LBD.
METHODS: The PRISMA guideline was followed for the systematic reivew. Three online databases were searched. Four RCTs and sixteen observational studies with 1142 LBD patients were analysed. The primary outcomes were back and leg pain scores, back-specific disability scores and expression of inflammatory biomarkers. Standardized mean difference (SMD) and their 95% confidence intervals (CI) were evaluated. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to summarize the strength of evidence.
RESULTS: Four RCTs and sixteen observational studies were included in the analysis of 1142 patients with LBD. There was a statistically significant reduction in back pain score and IL-1 beta and increase in the expression of CTX-1 and IL-10 levels post treatment. There was a significant relationship between increase in the expression of MCP- and reduction in the expression of hsCRP with increase in back pain. Significant relationship was also observed between increase in the expression of MCP-1 and reduction in the expression of IL-6 with increase in leg pain. Increase in the expression of IL-8 and reduction in the expression of hsCRP was also associated with increased disability score.
CONCLUSION: Inflammatory biomarkers play a significant role in the pathogenesis of LBD. CTX-1, IL-10 and IL-1 beta may be responsible for the decrease in back pain scores post treatment. There is a relationship between MCP-1, IL-6, IL-8 and hsCRP with clinical and functional assessments for LBD. Further studies will improve understanding of the pathogenesis of LBD and aid in targeted management strategies.
OBJECTIVES: I. Determine the tumor response of patients with refractory or relapsed multiple myeloma or Castleman's disease treated with suramin. II. Determine the effects of this regimen on cytokine-mediated symptoms in patients with Castleman's disease. III. Determine the overall and progression-free survival in patients with multiple myeloma or Castelman's disease treated with this regimen. IV. Determine the qualitative, quantitative, and cumulative toxic effects of this regimen in these patients. V. Determine the effect of this regimen on the levels of serum interleukin-6 (IL-6), soluble IL-6 receptor, and soluble gp130 in these patients.

OUTLINE: Patients receive suramin on days 1-5, 8, 11, 15, 19, 22, and 29. During course 1, patients also receive suramin on days 36, 43, 50, 57, 64, 71, and 78. Suramin is administered IV over 2 hours on day 1 of course 1 and over 1 hour on all subsequent infusion days. Patients undergo rest for at least 12 weeks between each course. Patients with responding disease after completion of course 2 may receive additional courses in the absence of unacceptable toxicity. Patients are followed weekly for 1 month, every 2 weeks for 1 month, at 3 months, and then monthly thereafter if indicated.

PROJECTED ACCRUAL: A total of 20-40 patients with multiple myeloma will be accrued for this study within 10-20 months. A total of 20-40 patients with Castleman's disease will be accrued for this study within 2.9-8 years.
Use of veno-venous extracorporeal oxygenation membrane is a therapeutic option for the management of the most severe patients with acute respiratory distress syndrome (ARDS). It allows to provide a protective lung ventilation by reducing the level of airway pressures generated by the ventilator. The objective is to minimize the harmful effects of mechanical ventilation in the lungs and to provide adequate gases exchanges. This strategy requires a deep sedation to allow a perfect synchrony between the patient and the ventilator. Such a synchrony puts the respiratory muscles - in particular the diaphragm - completely at rest.

Given the prolonged duration of this strategy, the question of its impact on the occurrence on diaphragm dysfunction has been raised. Such a dysfunction has been associated with prolonged duration of mechanical ventilation and poor outcomes but its effect in patients with veno-venous extracorporeal oxygenation membrane has never been evaluated so far.
The present disclosure provides a module for monitoring handling of various item(s). In some embodiments, the item(s) can include medications, e.g., leftover or unused medications. In an aspect, the present disclosure provides a method for monitoring medication wasting. The method can comprise generating a digital communication between a medication monitoring module and at least one sensor of a user device. The method can comprise directing, by the medication monitoring module, the at least one sensor to: (i) record disposal of a medication to a medication waste unit by a user, wherein the medication waste unit is not a part of the user device; and (ii) record the user prior to, during, or subsequent to the disposal of the medication by the user. The method can further comprise generating a plurality of digital data representative of the disposal and the user.
A cosmetic cartridge material in flowable state is filled directly into a sleeve H (which can be made pointed) of a cosmetic stick, and is subsequently solidified. In order to produce cosmetic sticks of cartridge thicknesses less than 6 mm with adequately high pigmenting and using constituents which are volatile at an elevated temperature (e.g. perfume oils) in a more simple way than hitherto, the sleeve is evacuated and the cartridge material sucked into one end of the sleeve under a partial vacuum. The apparatus alternatively includes means, Fig. 3 (not shown), for applying partial vacuum to said one end prior to pouring or means 51,52 for applying partial vacuum to the opposite end of the sleeve during pouring. <IMAGE>
The invention discloses an immunomodulatory peptide Og-CATH and application thereof. Belongs to the biomedical field. The immunoregulation peptide Og-CATH is a linear polypeptide coded by a rana grahami defensive peptide gene of a special species of China amphibian, has a molecular weight of 3078.59 daltons, an isoelectric point of 12.78, and an amino acid sequence shown as SEQ ID NO. 2. The gene for encoding the rana grahami immunoregulatory peptide Og-CATH precursor consists of 645 nucleotide sequences, and the nucleotide sequence is shown as SEQ ID NO. 1; wherein the 366 th to 450 th nucleotide is the coding gene of the mature rana grahami immunoregulatory peptide Og-CATH. The application of the rana grahami immunoregulatory peptide Og-CATH in preparing medicines for resisting methicillin-resistant staphylococcus aureus and carbapenem-resistant escherichia coli infection. The beneficial effects are that: has stronger regulation effect on main immune cells of a host, and can obviously resist methicillin-resistant staphylococcus aureus and carbapenem-resistant escherichia coli infection.